NCT04913038

Brief Summary

The ANI monitor is a medical device allowing to measure the response of the autonomic nervous system to a painful stimulus. In the pediatric population under general anesthesia, the ANI score can detect failure of locoregional anesthesia; ANI decreases after painful stimulation during surgery, more markedly with smaller doses of Remifentanil. To date, measurement of ANI in sedated children in pediatric intensive care has not been performed or validated as a method of assessing pain and discomfort.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 17, 2021

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 4, 2021

Completed
25 days until next milestone

Study Start

First participant enrolled

June 29, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 22, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2023

Completed
Last Updated

December 19, 2025

Status Verified

November 1, 2023

Enrollment Period

2.4 years

First QC Date

May 17, 2021

Last Update Submit

December 18, 2025

Conditions

Keywords

Intensive Care Units,Pain MeasurementANI, Analgesia Nociception IndexPediatric,

Outcome Measures

Primary Outcomes (3)

  • Analgesia Nociception Index (ANI) minimum

    at 10 minutes before the painful care

  • ANI minimum

    at 30 minutes (average lenght of painful care)

  • ANI minimum

    at 10 minutes after the painful care

Secondary Outcomes (4)

  • Variation of ANI minimum between before and after a painful care

    From 10 minutes before the care to 10 minutes after the care

  • the correlation between ANI minimum and the COMFORT B behavioral scale.

    From 10 minutes before the care to 10 minutes after the care

  • the ability of ANI minimum to distingush painful from non painful patient

    From 10 minutes before the care to 10 minutes after the care

  • Area under the ROC curve of ANI min calculated over all measurements

    From 10 minutes before the care to 10 minutes after the care

Study Arms (1)

case group

children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care.

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care

You may qualify if:

  • Prebubescent chilren (up to 2 years old) Admited in PICU Sedated, ventilated

You may not qualify if:

  • Non sinusal rythm
  • Atropine
  • Pace-macker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hop Jeanne de Flandre Chu Lille

Lille, 59037, France

Location

Related Publications (1)

  • Barat A, Wojtanowski A, Behal H, Flocteil M, Leteurtre S, De Jonckheere J, Recher M. Evaluation of the Analgesia Nociception Index (ANI) as an indicator of discomfort in deeply sedated, prepubescent patients. J Clin Monit Comput. 2026 Feb;40(1):203-209. doi: 10.1007/s10877-025-01355-2. Epub 2025 Sep 9.

MeSH Terms

Conditions

PainPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Morgan RECHER, MD

    University Hospital, Lille

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2021

First Posted

June 4, 2021

Study Start

June 29, 2021

Primary Completion

November 22, 2023

Study Completion

November 23, 2023

Last Updated

December 19, 2025

Record last verified: 2023-11

Locations